Abstract

ABSTRACTAllele-specific distinctions in the human apolipoprotein E (APOE) locus represent the best-characterized genetic predictor of Alzheimer's disease (AD) risk. Expression of isoform APOEε2 is associated with reduced risk, while APOEε3 is neutral and APOEε4 carriers exhibit increased susceptibility. Using Caenorhabditis elegans, we generated a novel suite of humanized transgenic nematodes to facilitate neuronal modeling of amyloid-beta peptide (Aβ) co-expression in the context of distinct human APOE alleles. We found that co-expression of human APOEε2 with Aβ attenuated Aβ-induced neurodegeneration, whereas expression of the APOEε4 allele had no effect on neurodegeneration, indicating a loss of neuroprotective capacity. Notably, the APOEε3 allele displayed an intermediate phenotype; it was not neuroprotective in young adults but attenuated neurodegeneration in older animals. There was no functional impact from the three APOE isoforms in the absence of Aβ co-expression. Pharmacological treatment that examined neuroprotective effects of APOE alleles on calcium homeostasis showed allele-specific responses to changes in ER-associated calcium dynamics in the Aβ background. Additionally, Aβ suppressed survival, an effect that was rescued by APOEε2 and APOEε3, but not APOEε4. Expression of the APOE alleles in neurons, independent of Aβ, exerted no impact on survival. Taken together, these results illustrate that C. elegans provides a powerful in vivo platform with which to explore how AD-associated neuronal pathways are modulated by distinct APOE gene products in the context of Aβ-associated neurotoxicity. The significance of both ApoE and Aβ to AD highlights the utility of this new pre-clinical model as a means to dissect their functional inter-relationship.This article has an associated First Person interview with the first author of the paper.

Highlights

  • Alzheimer’s disease (AD), characterized by the formation of insoluble amyloid-beta peptide (Aβ) plaques in the brain, accounts for nearly 70% of all late-life dementia

  • The APOEε4 allele is the strongest risk factor associated with late-onset AD, yet determining precisely how the apolipoprotein E (APOE) alleles differentially modulate Aβ toxicity and neuronal behavior remains unresolved

  • We debut a model of apolipoprotein E (ApoE) activity in our established neuronal C. elegans background and suggest that it can be exploited to examine the relationship between ApoE and Aβ for neuronal behavior, integrity and proteotoxicity

Read more

Summary

Introduction

Alzheimer’s disease (AD), characterized by the formation of insoluble amyloid-beta peptide (Aβ) plaques in the brain, accounts for nearly 70% of all late-life dementia. Estimates vary based on study and ethnicity, ∼40% of AD cases harbor the ε4 allele of APOE (Spinney, 2014). This allele is a significant risk factor for late-onset AD, where two copies of APOEε4 increases AD risk up to 15-fold relative to APOEε3. There may be opposing actions of the APOEε2 and APOEε4 alleles, which would not be unprecedented, as APOEε2 and APOEε4 appear to have opposing activities in lipidation and aggregate stabilization (Hu et al, 2015) Despite this correlation, the mechanisms by which differences in APOE allelic function modify AD risk are not entirely understood

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call